Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Phase 2 Active not recruiting

250 enrolled 2 FDA

GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT00734305 2016-09-01

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Phase 1 Completed

44 enrolled 12 charts

Lethal Congenital Contracture Syndrome 2, Neoplasms

NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

162 enrolled 11 charts

Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Phase 1 Completed

60 enrolled

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2